Targeting HER2 by Combination Therapies.
作者信息
Ruiz-Saenz Ana, Moasser Mark M
机构信息
Ana Ruiz-Saenz, University of California at San Francisco, San Francisco, CA; and Mark M. Moasser, University of California at San Francisco, San Francisco, CA.
出版信息
J Clin Oncol. 2018 Mar 10;36(8):808-811. doi: 10.1200/JCO.2017.77.1899. Epub 2018 Jan 30.
Abstract
摘要
相似文献
1
Targeting HER2 by Combination Therapies.
J Clin Oncol. 2018 Mar 10;36(8):808-811. doi: 10.1200/JCO.2017.77.1899. Epub 2018 Jan 30.
2
Neratinib, A Novel HER2-Targeted Tyrosine Kinase Inhibitor.
Clin Breast Cancer. 2016 Oct;16(5):344-348. doi: 10.1016/j.clbc.2016.05.016. Epub 2016 May 29.
3
Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.
Oncology (Williston Park). 2005 Nov;19(13 Suppl 5):5-16.
4
HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications.
Oncology (Williston Park). 1997 Mar;11(3 Suppl 2):43-8.
5
Role of trastuzumab in patients with brain metastases from Her2 positive breast cancer.
J Neurooncol. 2008 Jan;86(2):241. doi: 10.1007/s11060-007-9447-7. Epub 2007 Jul 6.
6
"Vertical" Inhibition of HER2 Yields Horizontal Gains in the Clinic.
Clin Cancer Res. 2015 Jun 15;21(12):2663-5. doi: 10.1158/1078-0432.CCR-14-3183.
7
Progression and treatment of HER2-positive breast cancer.
Cancer Chemother Pharmacol. 2010 Mar;65(4):611-23. doi: 10.1007/s00280-009-1208-1. Epub 2009 Dec 20.
8
Targeting HER2 in Advanced Breast Cancer.
Methods Mol Biol. 2017;1652:63-77. doi: 10.1007/978-1-4939-7219-7_4.
9
[Brain metastases in breast cancer: a special disease course for HER2 positive tumors].
Ned Tijdschr Geneeskd. 2008 Dec 13;152(50):2701-6.
10
Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer.
Clin Cancer Res. 2015 Jun 15;21(12):2737-44. doi: 10.1158/1078-0432.CCR-14-1812. Epub 2014 Nov 4.
引用本文的文献
1
ADCC: the rock band led by therapeutic antibodies, tumor and immune cells.
Front Immunol. 2025 Apr 16;16:1548292. doi: 10.3389/fimmu.2025.1548292. eCollection 2025.
2
A co-culture model system to quantify antibody-dependent cellular cytotoxicity in human breast cancer cells using an engineered natural killer cell line.
STAR Protoc. 2023 Apr 17;4(2):102224. doi: 10.1016/j.xpro.2023.102224.
3
Targeting receptor tyrosine kinases in ovarian cancer: Genomic dysregulation, clinical evaluation of inhibitors, and potential for combinatorial therapies.
Mol Ther Oncolytics. 2023 Feb 19;28:293-306. doi: 10.1016/j.omto.2023.02.006. eCollection 2023 Mar 16.
4
A Novel Homodimer Peptide-Drug Conjugate Improves the Efficacy of HER2-Positive Breast Cancer Therapy.
Int J Mol Sci. 2023 Feb 27;24(5):4590. doi: 10.3390/ijms24054590.
5
Ultrasound-triggered herceptin liposomes for breast cancer therapy.
Sci Rep. 2021 Apr 6;11(1):7545. doi: 10.1038/s41598-021-86860-5.
6
Combining losartan with radiotherapy increases tumor control and inhibits lung metastases from a HER2/neu-positive orthotopic breast cancer model.
Radiat Oncol. 2021 Mar 4;16(1):48. doi: 10.1186/s13014-021-01775-9.
7
Massively parallel sequencing analysis of 68 gastric-type cervical adenocarcinomas reveals mutations in cell cycle-related genes and potentially targetable mutations.
Mod Pathol. 2021 Jun;34(6):1213-1225. doi: 10.1038/s41379-020-00726-1. Epub 2020 Dec 14.
8
Targeting of HER/ErbB family proteins using broad spectrum Sec61 inhibitors coibamide A and apratoxin A.
Biochem Pharmacol. 2021 Jan;183:114317. doi: 10.1016/j.bcp.2020.114317. Epub 2020 Nov 3.
9
Transformable peptide nanoparticles arrest HER2 signalling and cause cancer cell death in vivo.
Nat Nanotechnol. 2020 Feb;15(2):145-153. doi: 10.1038/s41565-019-0626-4. Epub 2020 Jan 27.
10
Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities.
Nat Cell Biol. 2019 Jun;21(6):778-790. doi: 10.1038/s41556-019-0328-z. Epub 2019 Jun 3.
本文引用的文献
1
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol. 2017 Dec;18(12):1688-1700. doi: 10.1016/S1470-2045(17)30717-9. Epub 2017 Nov 13.
2
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
N Engl J Med. 2017 Jul 13;377(2):122-131. doi: 10.1056/NEJMoa1703643. Epub 2017 Jun 5.
3
First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors.
Ann Oncol. 2017 Apr 1;28(4):855-861. doi: 10.1093/annonc/mdx002.
4
Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.
JAMA Oncol. 2016 Dec 1;2(12):1557-1564. doi: 10.1001/jamaoncol.2016.0237.
5
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1.
Clin Cancer Res. 2016 Oct 15;22(20):5097-5108. doi: 10.1158/1078-0432.CCR-15-2822. Epub 2016 Mar 29.
6
Antibody targeting facilitates effective intratumoral siRNA nanoparticle delivery to HER2-overexpressing cancer cells.
Oncotarget. 2016 Feb 23;7(8):9561-75. doi: 10.18632/oncotarget.7076.
7
Development of anti-HER2 fragment antibody conjugated to iron oxide nanoparticles for in vivo HER2-targeted photoacoustic tumor imaging.
Nanomedicine. 2015 Nov;11(8):2051-60. doi: 10.1016/j.nano.2015.07.007. Epub 2015 Jul 31.
8
Targeting HER3 by interfering with its Sec61-mediated cotranslational insertion into the endoplasmic reticulum.
Oncogene. 2015 Oct 8;34(41):5288-94. doi: 10.1038/onc.2014.455. Epub 2015 Jan 26.
9
Function-blocking ERBB3 antibody inhibits the adaptive response to RAF inhibitor.
Cancer Res. 2014 Aug 1;74(15):4122-32. doi: 10.1158/0008-5472.CAN-14-0464. Epub 2014 Jul 17.
10
RETRACTED: An ATP-competitive inhibitor modulates the allosteric function of the HER3 pseudokinase.
Chem Biol. 2014 Apr 24;21(4):453-458. doi: 10.1016/j.chembiol.2014.02.011. Epub 2014 Mar 20.
Zotero 插件